Hematology & Oncology
Showing 31-40 of 55 Results
-
Clara Lo
Clinical Professor, Pediatrics - Hematology & Oncology
Current Research and Scholarly InterestsResearch interests include:
Biomarkers and targeted therapy in pediatric immune thrombocytopenia
Transfusion-related iron overload
Hemophilia and other rare bleeding disorders
Thrombophilia -
Adrienne H. Long, MD, PhD
Instructor, Pediatrics - Hematology & Oncology
BioAdrienne H. Long, MD, PhD is an Instructor and Physician-Scientist in the Division of Pediatric Hematology and Oncology at the Lucile Packard Children's Hospital, Stanford. Clinically, she completed her MD at Northwestern University, her pediatrics residency at Boston Children’s Hospital, and her oncology fellowship training at Stanford University. Dr. Long sees patients with leukemias/lymphomas, and has a clinical interest in T cell malignancies.
Dr. Long received her PhD in Microbiology/Immunology through a National Institutes of Health (NIH) – Northwestern University partnership, where she worked with Dr. Crystall Mackall to advance CAR T cell therapies. Her influential thesis work was the first to identify T cell exhaustion as a critical factor limiting efficacy of CAR therapies (Long et al., Nature Medicine, 2015). She continued her research training with Dr. Nicholas Haining at the Dana Farber Cancer Institute during residency and is currently conducting her post-doctoral research with Dr. Mark Davis at Stanford.
Dr. Long’s research interests lie at the intersection of the immune system and cancer therapies. She is currently studying how thymic selection, designed to prevent auto-immunity, may also inhibit anti-tumor immunity in children. She is also interested in how immunotherapies that have revolutionized how we treat cancer can impact the developing pediatric immune system long term. -
Crystal Mackall
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly InterestsRecent clinical studies, by us and others, have demonstrated that genetically engineered T cells can eradicate cancers resistant to all other therapies. We are identifying new targets for these therapeutics, exploring pathways of resistance to current cell therapies and creating next generation platforms to overcome therapeutic resistance. We have discovered novel insights into the biology of human T cell exhaustion and developed approaches to prevent and reverse this phenomenon.
-
Neyssa Marina
Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emerita
Current Research and Scholarly InterestsGerm cell tumors and bone sarcomas.
-
Allison Pribnow
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
Current Research and Scholarly InterestsSolid Tumors, Bone Sarcomas, Global Oncology, Health Disparities
